Multicenter pivotal trial results of the Lifepath System for endovascular aortic aneurysm repair  by Carpenter, Jeffrey P et al.
From the Society for Vascular Surgery
Multicenter pivotal trial results of the Lifepath
System for endovascular aortic aneurysm repair
Jeffrey P. Carpenter, MD, William N. Anderson, PhD, David C. Brewster, MD, Chris Kwolek, MD,
Michel Makaroun, MD, John Martin, MD, Richard McCann, MD, James McKinsey, MD, and Hugh G.
Beebe, MD, for the Lifepath Investigators*
Purpose: This study was undertaken to assess the results of endovascular aortic aneurysm repair with the Lifepath
abdominal aortic aneurysm (AAA) graft system.
Method: In a prospective clinical trial, 23 centers used the Lifepath System balloon-expandable, modular bifurcated stent
graft for elective endovascular aortic aneurysm repair. Stent grafts were sized according to computed tomographic
angiography–based diameter measurements. All repairs were performed in the operating room through bilateral
surgically exposed femoral arteries. Results were assessed with contrast agent–enhanced computed tomography scans and
plain abdominal x-ray films at 1, 6, 12, 24, 36, and 48 months postoperatively.
Results: Over 52 months (mean follow-up, 11 months), 227 patients (206 men, 21 women) were enrolled. Technical
implant success rate was 98.7%. There were five (2.2%) conversions to open surgery: two emergently because of aortic
perforation; to treat refractory endoleak, immediate in one and at 12 months in one; and to replace a device with wireform
fractures that had migrated at 12 months, resulting in a proximal endoleak. The perioperative mortality rate was 1.3%.
There was one operative death during a secondary procedure to repair perforation of the aorta. There were two
perioperative deaths, from postoperative myocardial infarction (n  1) and pulmonary embolus (n  1). There were 12
late deaths, from coronary artery disease (n  4), cancer (n  2), respiratory failure (n  2), sepsis (n  1), or unknown
cause (n  3). Median length of stay was 2 days (mean, 4 days). There have been no AAA ruptures after successful
implantation of the device, no graft limb thromboses, and no limb dislocations. At the time of operation endoleak was
noted in 43 (19%) patients, but by 6 months this was reduced to 8 (5.9%) patients (type I, n  1; type II, n  7). There
were no type III or type IV endoleaks. Secondary interventions to treat endoleaks included open conversion (n  2),
placement of extension cuffs (n 4), repeated balloon dilation (n 3), and coil embolization (n 6). The two remaining
secondary interventions were emergent treatment of postoperative bleeding from a groin incision, and a colon resection
because of postoperative colonic ischemia, for a 12-month secondary intervention rate of 7.5%. Wireform fractures were
noted in the first generation Lifepath device in 37 of 79 (47%) patients. Graft migration (>10 mm) was observed in five
patients (2.2%), each of whom also had two or more fractures of the proximal anchoring wireforms. Migration resulted
in a proximal attachment endoleak in one patient. In response to wireform fractures, the device was modified after the
initial 79 patients were enrolled. Wireform fracture has been observed in six patients since this modification (4%), and in
only one patient did this involve fracture of a proximal anchoring wireform; none of these patients has had endoleak or
graft migration. By 12 months, mean aneurysm diameter was noted to decrease by 9 mm (P < .0001), and mean aneurysm
volume by 42 mL (P < .0001) from the preoperative visit.
Conclusion: The Lifepath System demonstrates a low endoleak and secondary intervention rate and high sac regression
rate, compared with other devices. The unique balloon-expandable design offers the advantages of precise placement and
high radial force. The device appears to be highly resistant to limb thrombosis and modular component separation.
Patients were protected from AAA rupture after successful device implantation, and demonstrated significant reduction
in AAA diameter and volume. Fractures of the wireforms of the main body of the device have been observed. Careful
long-term follow-up is necessary. (J Vasc Surg 2004;39:34-43.)
The Lifepath abdominal aortic aneurysm (AAA) graft
system is an adaptation of the White-Yu endovascular graft
attachment device (GAD) described in 1994.1 The
White-Yu device was constructed from a commercially
available polyester prosthesis with a patented intrinsic wire-
form graft attachment system along the graft body. Initial
bench model studies led to design enhancements that
eventually allowed safe use in human beings. Three years of
experience with the White-Yu Endovascular GAD graft was
reported in 1997.2 In this latter series, the 30-day mortality
rate for elective endoluminal AAA repair was 3.1%; primary
endoleak occurred in five patients (5.4%), all during the first
15 months of the prototype clinical trial; and secondary
endoleak was noted in three patients (3.2%). There were
seven perioperative conversions (7.3%), because of causes
unrelated to endoleak, and no late conversions in the
bifurcated device implants. Decrease in the size of the
aneurysm sac was consistently observed in the successfully
treated cases. From this experience, it was concluded that
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the White-Yu device appeared to safely and effectively
exclude aneurysms from blood flow. The success of this
study led to development of the commercially designed and
developed product by Edwards Lifesciences LLC (Irvine,
Calif; formerly Baxter Cardiovascular Group). We report
the results of a multicenter clinical trial of the Lifepath
System for repair of nonruptured infrarenal aortic aneu-
rysms.
METHODS
A trial of the safety and efficacy of the Lifepath System
was conducted at 23 centers (Appendix). This device is
under Investigational Device Exemption in the United
States in the context of a pivotal Food and Drug Adminis-
tration trial. Each center obtained approval from its insti-
tutional review board for human subject investigations, and
informed consent was obtained from all patients.
Device. The Lifepath System is a modular, bifurcated,
balloon-expandable endovascular graft. The stented en-
doskeleton is constructed from Elgiloy (Elgiloy Limited
Partnership, Elgin, Ill), a metal alloy with high chromium
content. Individual wireforms are interwoven through the
graft material in concentric ring fashion, separated by re-
gions of unsupported graft, to allow flexibility and sealing.
The graft fabric is woven polyester, provided in a full,
surgical-weight thickness. In addition to radial force alone,
external metallic crimps help to achieve secure fixation. The
main graft body consists of a balloon-expandable trunk
with two self-expanding legs. The self-expanding legs are
comprised of specially treated Elgiloy sewn externally on
the polyester fabric (Fig 1, A). The iliac grafts are balloon-
expandable in their entirety, and are comprised of indepen-
dent concentric Elgiloy wireforms interwoven through the
polyester graft fabric, with external crimps. Main body
grafts are supplied in neck diameters from 21 to 29 mm,
with aortic cuffs up to 31 mm, and are suitable for repair of
aneurysms with neck diameters ranging from 19 to 27 mm.
Main body grafts are uniform in diameter. Aortic necks of
irregular or tapered diameter may be treated by combining
a main body of one diameter with a proximal extender cuff
of a different diameter, deploying the larger device into the
smaller device to create a seal. Iliac limbs are straight or
tapered in diameter along their length, with a common
proximal end designed to securely dock with the main body
Fig 1. Lifepath System is a balloon-expandable, modular stent graft consisting of a main body (A) and docking limbs
(not shown). Proximal and distal extension cuffs in various sizes are available. Grafts are premounted on balloons that
have square shoulders, and are also supplied separately. Stent grafts are delivered through flexible, hydrophilic sheaths
supplied in 25F and 19F (OD) sizes. B, A directional catheter, shown with a cut-away view of the main body stent graft,
facilitates cannulation of the contralateral limb by means of a moveable tip, which can be deflected with a hand control
located at the back of the catheter.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 1 Carpenter et al 35
graft, and a distal limb diameter chosen to seal appropri-
ately in the desired distal iliac landing zone. Both proximal
and distal extension cuffs, which are not tapered in diame-
ter, are available. The grafts are supplied premounted on
balloon catheters, and are delivered through highly flexible,
hydrophilic sheaths: the main body through a 25F (outside
diameter [OD]) sheath, and the iliac legs through a 19F
(OD) sheath. Balloons in all sizes are also available
separately.
Device insertion procedure. The device is delivered
via surgically exposed femoral arteries. Initially, wire access
through the aneurysm to the thoracic aorta is established.
After completion of the arterial exposure, heparin is admin-
istered for systemic anticoagulation. Through ipsilateral
femoral access, the 25F sheath is fluoroscopically guided
over a stiff guide wire into the abdominal aorta to a level
slightly proximal to the renal arteries. Through the con-
tralateral femoral access route a flush angiographic catheter
is placed, and an arteriogram is obtained to identify the
precise location of the renal arteries. After thorough flush-
ing with a high-concentration heparin flush, the Lifepath
System main body graft is placed over the wire and loaded
into the sheath. It is fluoroscopically guided within the
sheath into position at the level of the lowest renal artery.
Once positioned properly with respect to both level of the
renal arteries and orientation of left and right limb markers,
the graft is unsheathed, allowing the self-expanding legs to
open, but with the main body remaining crimped on the
balloon (Fig 2, A). Fine adjustments may be made with
respect to device positioning and rotation. Balloon inflation
is performed in a slow, controlled fashion, allowing precise
deployment at the renal artery level. Repeat balloon infla-
tion is used to ensure full expansion of the wireforms and
secure the graft to the aortic neck. The balloon is then
withdrawn. A mechanism on the delivery catheter for
lengthening the balloon (stretching), thereby reducing its
deflated diameter, may be used to reduce the balloon
profile after deflation and facilitate balloon removal. Con-
tralateral limb wire access is established either retrograde,
through cannulation of the main graft body leg from the
contralateral femoral access, or antegrade, through retrieval
of a wire passed down through the contralateral limb from
the ipsilateral access route already established. This latter
maneuver is facilitated by use of a directional catheter
supplied with the Lifepath System (Fig 1, B). This dual-
lumen catheter is passed over the established ipsilateral
access wire and positioned above the flow divider of the
main body of the stent graft. The deflecting tip of the
directional catheter is then fully deflected to enable a flex-
ible guide wire to be passed through the catheter, down
and out the contralateral leg, to be retrieved through the
contralateral access (snare or open femoral retrieval). Suc-
cessful cannulation is confirmed by visualizing the wire
exiting the contralateral leg. Once access to the contralat-
eral leg has been established, a stiff wire exchange is per-
formed. Sheaths are advanced over the stiff wires positioned
through both the ipsilateral and contralateral legs of the
main graft body, to prepare for docking the iliac graft limbs.
Fig 2. Device insertion procedure (see text for details). A, Main body deployment. The two legs of the main graft body
are self-expanding. B, Iliac limb deployment with balloon inflation.
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On the ipsilateral side, the previously placed 25F sheath is
advanced into the leg of the main body, and on the con-
tralateral side a 19F sheath is advanced into the contralat-
eral leg of the main body. After flushing with a high-
concentration heparin solution to remove air from the
system, the iliac stent grafts are advanced through their
respective sheaths into position, fully within the main body
legs (Fig 2, B). They are unsheathed, and deployed with
balloon inflation. These legs may be deployed sequentially
or with the kissing balloon technique. Repeat balloon
inflation is performed to ensure full expansion of the wire-
forms. A final arteriogram is obtained. At the conclusion of
the procedure, the sheaths are withdrawn, the arterioto-
mies created for the procedure are closed, and the hepa-
rinization may be reversed with administration of prota-
mine sulfate, at the discretion of the operator.
Patient selection. Only patients with nonruptured in-
frarenal aortoiliac aneurysms who were candidates for con-
ventional open AAA repair were enrolled. Inclusion and
exclusion criteria are shown in Table I.
The anatomic suitability for endovascular repair was
determined with computed tomographic angiography
(CTA) for the first-generation design, and additionally with
three-dimensional reconstruction by the central core labo-
ratory (originally, Imaging Sciences Institute, University
Hospital, Utrecht, The Netherlands; currently, Medical
Media Systems, Lebanon, NH). Routine preoperative cath-
eter angiography was not performed.
Device selection. Preoperative measurements of the
aneurysm neck diameter (intima-to-intima) were used to
determine the appropriate diameter of the stent graft main
body. Inasmuch as the device was balloon-expandable,
minimal oversizing (10%-15%) was used. Graft selection
was suggested by the core laboratory, but was ultimately at
the discretion of the implanting surgeon. Graft length was
chosen so as not to cover more than one, and preferably
neither, hypogastric artery.
Follow-up evaluation. Patients underwent baseline
abdominal plain radiography at device implantation and
before hospital discharge. In addition to physical examina-
tion, abdominal four-view (anteroposterior, lateral, left and
right anterior oblique) x-ray studies and CTA were per-
formed at 1, 6, and 12 months, and annually thereafter.
These studies were used to assess the integrity of the stent
graft and the aneurysm repair (migration, wire fractures,
endoleak, aneurysm size). Studies were evaluated at each
local site as well as independently by the central core
laboratory. Reporting of results complied with the report-
ing standards for endovascular AAA repair.3
Statistical analysis. For continuous variables, means
and ranges are presented; where appropriate, 95% confi-
dence limits were computed with the t distribution, and
groups were compared with the two-sample t test or paired-
sample t test. For binary variables, confidence limits were
computed with the exact binomial distribution, and groups
were compared with the Fisher exact test. Kaplan-Meier
survival analysis was performed with the log-rank test for
significance. All computations were performed with SAS
software (version 8.2; SAS Institute, Cary, NC); unless
otherwise specified, the exact form of each algorithm is the
SAS default.
RESULTS
Patients and procedures. Beginning in December
1998 and continuing over 52 months, endovascular repair
of AAA was successfully performed in 224 of 227 (98.7%)
patients with the Lifepath System. Patient demographic
data are shown in Table II. After the initial 79 patients
(“generation 1”) were enrolled, the trial was voluntarily
suspended to allow strengthening of the System wireforms,
in response to observed wireform fractures (see below).
Enrollment was then resumed (“generation 2”) after an
enrollment hiatus of 18 months. Overall follow-up ranged
from 0 to 41 months (mean, 11 months). For generation 1,
mean follow-up was 25 months (median, 24 months), and
for generation 2 patients, mean follow-up was 3 months
(median, 3 months).
There were five (2.2%) conversions to open surgery:
emergently because of aortic perforation (one intraopera-
tive, one several hours postoperative), to treat refractory
endoleaks (one immediate, one at 6 months), and for
replacement of a device with wireform fractures that had
migrated, resulting in a proximal endoleak (one, at 12
months). The aortic perforations were thought to be re-
lated to excessive stretching of the aortic neck during
balloon inflation, resulting in disruption. Devices used are
listed in Table III. Proximal extension cuffs were placed in
40 (17.6%) patients, and distal extensions in 46 (20.3%)
patients. Most of the proximal cuffs were planned place-
ments, to accommodate irregularly shaped aneurysm necks
Table I. Inclusion and exclusion criteria
Acceptable surgical candidate for traditional open infrarenal AAA
repair (surgeon’s discretion)
Saccular AAA of any size
Age 40–85 years
Patient available for 3-year follow-up
Acceptable cardiac, pulmonary, renal, and hepatic function
Fusiform AAA 5 cm diameter or 4-5 cm with at least one of
the following:
Double diameter of normal aorta
Evidence of growth over 1 year 0.5 cm
Symptoms of back or abdominal pain or tenderness to AAA
palpation
Younger than 65 years
Family history of aneurysm (first degree or primary relative)
Aneurysm proximal neck length 15 mm
Proximal neck diameter 19-27 mm
Renal-aortic bifurcation length 90 mm
Proximal neck angulation 60 degrees
Iliac artery diameter in attachment zone suitable for iliac graft
limb
Attachment zone nonaneurysmal, 15 mm long
Diameter of ipsilateral access arteries will accommodate 25F
(OD) sheath
Diameter of contralateral access arteries will accommodate 19F
(OD) sheath
AAA, Abdominal aortic aneurysm; OD, outside diameter.
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rather than to treat endoleaks or malpositioning of the main
body. Unplanned cuff placement for endoleak remediation
is discussed below. The details of the operative procedures
are shown in Table IV. Median length of stay (LOS) after
endovascular aortic aneurysm repair was 2 days (mean, 4
days; range, 1-33 days).
Mortality. There were 15 deaths (3 perioperative, 12
late) during follow-up. Of the 3 perioperative deaths
(1.3%), 1 resulted from aortic perforation, noted after
transfer to the intensive care unit, necessitating immediate
return to the operating room and open conversion, with
fatal outcome. The remaining perioperative deaths were
from myocardial infarction (n  1) and pulmonary embo-
lus (n  1). The 12 late deaths were from coronary artery
disease (n 4), cancer (n 2), respiratory failure (n 2),
sepsis (n  1), or unknown cause (n  3).
Complications and secondary procedures. Periop-
erative complications are listed in Table V. There have been
no aneurysm ruptures after successful placement of the
LifePath System, and no limb thromboses or dislocations
during follow-up.
Details of the number and type of endoleaks and the
interventions used to treat them are shown in Table VI.
Endoleak was noted at the operative procedure in 43 (19%)
patients, but by 1 month this was reduced to 25 (12.2%)
patients (type I, n  7; type II, n  18). All type I leaks
noted at the initial procedure were treated with additional
ballooning or placement of cuffs. All remaining type I
endoleaks detected subsequently were treated with second-
ary interventions (placement of extension cuffs, n  4;
repeat balloon dilation, n  3). Spontaneous sealing oc-
curred in 6 of the type II endoleaks, and 5 were treated with
secondary intervention (coil embolization, n  4; open
conversion of a type II endoleak that preoperatively was
thought to be type I, n  1), resulting in an endoleak rate
of 5.9% at 6 months. By 12 months a new type I endoleak
developed secondary to graft migration (see below), and
was treated with open conversion. Of the remaining type II
endoleaks, 2 were treated with coil embolization, and one
patient died of late myocardial infarction. A single remain-
ing type II endoleak is being observed. There were no type
III or type IV endoleaks.
Additional secondary procedures, other than those de-
scribed to treat endoleaks, included an emergent return to
Table II. Patient demographic data
Characteristic n (227) %
Coronary artery disease 121 53.3
Myocardial infarction 70 30.8
CABG (or PTCA) 72 31.7
Congestive heart failure 19 8.4
Arrhythmia 53 23.3
COPD 63 27.8
Renal disease 34 15.0
Diabetes 29 12.8
Hypertension 145 63.9
Peripheral vascular disease 31 13.7
Hyperlipidemia 111 48.9
Gastrointestinal disease* 82 36.1
Stroke (or TIA) 19 8.4
ASA class I 14 6.2
ASA class II 80 35.6
ASA class III 130 57.8
ASA class IV 1 0.4
ASA class unknown 2 0.9
CABG, Coronary artery bypass grafting; PTCA, percutaneous transluminal
coronary angioplasty; COPD, chronic obstructive pulmonary disease; TIA,
transient ischemic attack; ASA, American Society of Anesthesiologists.
*Includes cirrhosis, hepatitis, inflammatory bowel diseases, colorectal ma-
lignancy, multiple abdominal surgeries (“hostile abdomen”).
Table III. Devices deployed
Component n %
Main body (mm)
29 25 11.1
27 35 15.5
25 87 38.5
23 74 32.7
21 5 2.2
Iliac limbs (mm)
10  90 6 1.1
10  110 4 0.8
12  90 36 6.8
12  110 64 12.0
14  90 47 8.8
14  110 206 38.7
16  90 50 9.4
16  110 91 17.1
18  90 13 2.4
18  110 15 2.8
Proximal extension cuff 40 17.6
Distal extension 46 20.3
Table IV. Details of operative procedures
Event Mean Range %
Operating room time (min) 92.2 30-275
Fluoroscopy time (min) 32.0 11-130
Contrast agent (mL) 139.8 8-487
Regional anesthesia 62 27.3
General anesthesia 146 64.3
Local anesthesia 14 1.8
Regional and general anesthesia 4 1.8
Local and general anesthesia 1 0.4
Estimated blood loss (mL) 350.3 0-7300
Table V. Perioperative complications
Complication n %
Wound* 27 11.9
Pulmonary 6 2.6
Aortic perforation 2 0.9
Myocardial infarctive 1 0.4
Pulmonary embolus 1 0.4
Atheroembolic 1 0.4
Colon ischemia 1 0.4
*Includes all infections, hematomas, and seromas.
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the operating room for treatment of bleeding from a groin
incision, and a colon resection to treat postoperative co-
lonic ischemia. The total secondary intervention rate was
thus 7.5% at 12 months.
Wireform fractures and migration. The LifePath
System main body has four balloon-expandable wireforms.
The first three of these create the anchoring seal to the
aortic neck, and the fourth nonsealing wireform provides
structural support for the self-expanding docking limbs
during deployment. Integrity of the wireforms was evalu-
able with x-ray studies in 79 (100%) generation 1 patients
and 117 (81%) generation 2 patients. Wireform fractures
were noted in the first-generation Lifepath device in 37 of
79 (47%) patients. All fractures were noted to be in the
balloon-expandable segment of the main body. Fractures
were located in the first three anchoring wireforms in 33 of
these 37 patients, and in the nonanchoring fourth wireform
in 4 patients. No wireform fractures of the iliac limbs have
been observed. Trial enrollment was voluntarily suspended,
and the wireform thickness was increased. Wireform fractures
have been noted in the main body components in 6 (4%)
patients receiving the second-generation Lifepath System with
the strengthened wireforms. Fractures were in the anchoring
wireforms in only 1 patient, and in the nonanchoring fourth
wireform in the remaining 5 patients. While there is no signif-
icant difference between generation 1 and generation 2 pa-
tients overall for wireform fracture-free survival, when only the
critical anchoring wireforms are considered, generation 2 pa-
tients have significantly better fracture-free survival than do
generation 1 patients (P .0047; Fig 3).
Device migration (defined as movement10 mm) was
observed in the first-generation graft in five (2.2%) patients,
Table VI. Endoleaks and endoleak interventions
Operative
Follow-up
1 Mo 6 Mo 12 Mo 24 Mo
Endoleak
Type I 22 7 1 1 0
Type II 21 18 7 4 0
None 183 179 127 69 57
Endoleak rate (%) 19 12.2 5.9 6.8 0
Total patients 226 205 136 74 57
Type I interventions
Balloon 8 2 1 0 0
Cuff/extension 9 3 1 0 0
Conversion 1 0 0 1 0
Type II interventions
Coil embolization 1 1 3 2 0
Conversion 0 0 1 0 0
Total procedures 19 6 6 3 0
Fig 3. Kaplan-Meier analysis of anchoring wireform fractures for first-generation and second-generation Lifepath
System.
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each of whom also had two or more fractures of the
proximal anchoring wireforms. Three migrations were
noted at 12 months, and two migrations at 24-month
follow-up. Of these five migrations, one resulted in a prox-
imal attachment endoleak, and the remainder are not clin-
ically significant. No migrations have been noted in patients
receiving the second-generation Lifepath System.
Aneurysm diameter and volume before and after
EVAR. The average aneurysm diameter treated was 55
mm (range, 37-90 mm; median, 53 mm), and volume was
154 mL (range, 61-537 mL; median, 139 mL). Aneurysm
diameter and volume reduction were significant at each
assessment (Fig 4). Mean aneurysm diameter decreased by
3 mm at 6 months (P  .0001), an additional 4 mm at 12
months (P .0001), and an additional 3 mm at 24 months
(P  .0001). Similarly, mean aneurysm volume decreased
by 10 mL at 6 months (P .0012), an additional 12 mL at
12 months (P  .0001), and an additional 7 mL at 24
months (P  .0001). Overall, reduction of diameter was
noted in 58% of aneurysms, and reduction of volume was
noted in 84% at 12 months (Table VII). Enlargement of
aneurysms was noted in 7 patients by diameter and in 18
patients by volume measurement at some point during
follow-up. Wireform fractures were not observed in any of
these patients with expanding aneurysms. However, en-
doleak was observed in most of these patients (5 diameter
increases, 9 volume increases), and correction of these
endoleaks resulted in subsequent sac shrinkage. All type I
endoleaks resulted in AAA sac expansion. Expansion was
observed in the absence of endoleak in 2 patients by diam-
eter and in 9 patients by volume. Of the two diameter
expansions without endoleak, one spontaneously regressed
after 6 months, and the other increased by 5 mm at 1 year
and is being observed. Of the nine volume expansions
without endoleak, four spontaneously regressed after initial
expansion, and five (increase by 4, 9, 10, 16, and 22 mL,
respectively) are being observed.
DISCUSSION
We conducted a multicenter trial of the Lifepath Sys-
tem for endovascular repair of AAA in 227 patients over 52
months, and achieved a technical success rate of 98.7%,
perioperative mortality rate of 1.3%, and few serious com-
plications. The Lifepath System was effective in protecting
patients from AAA rupture after successful implantation,
with no late ruptures during follow-up, and significant
reduction in AAA diameter and volume at each follow-up
examination.
The Lifepath System is unique among EVAR devices. It
is balloon-expandable, which distinguishes it from all other
currently available stent grafts. This feature enables the
graft to be delivered with great precision to the desired
location, as evidenced by the low rate of cuff placement to
treat proximal attachment endoleaks at implantation
(3.9%). The stent graft has extremely high radial force and
hoop strength, as is generally associated with balloon-
expandable stents. This may be responsible for the com-
plete absence of iliac limb thrombosis, a phenomenon that
has plagued other EVAR devices.4 The main body and the
iliac graft limbs are supported by balloon-expandable
stents, arranged in concentric rings, to enable both radial
force and flexibility. This high radial force also enables tight
apposition of modular components, as evidenced by the
absence of any occurrences of component separation in this
trial. In contrast, component separation was responsible for
late AAA rupture after EVAR with other devices.5
We found that the graft performs well even in challeng-
ing angulated neck anatomy. In such cases, the balloon-
expandable stents significantly straighten the angulated
neck, providing a strong seal. Often with self-expanding
stent grafts it is difficult to obtain a seal in angulated necks,
and remedial procedures for leaking self-expanding stent
grafts in such situations usually include use of a balloon-
expandable stent or additional proximal cuff to provide
Fig 4. Abdominal aortic aneurysm diameter and volume change
after endovascular aortic aneurysm repair. Reduction in diameter
and volume is significant at each follow-up. Mean ( SE) aneu-
rysm diameter decreased by 3 mm at 6 months (P  .0001), an
additional 7 mm at 12 months (P  .0001), and an additional 3
mm at 24 months (P  .0001). Similarly, mean ( SE) aneurysm
volume decreased by 15 mL at 6 months (P  .0012), an addi-
tional 28 mL at 12 months (P .0001), and an additional 12 mL
at 24 months (P  .0002). See Table VII for details of diameter
and volume change at each follow-up.
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added radial sealing force.6 The Lifepath System provides
this additional force from the outset.
Because the stent graft is provided as a stented graft
premounted on a balloon, components are delivered
through sheaths. The sheaths provided with the System are
extremely flexible and hydrophilic, with long, smoothly
tapered dilators. The advantages of working through
sheaths include decreased blood loss and the ability to
negotiate tortuous or difficult anatomy with a flexible
sheath rather than a more rigid stent-graft delivery system.
The Lifepath System also includes a directional catheter
(Fig 1), which can greatly simplify the process of contralat-
eral limb cannulation. This offers the operator the option of
antegrade or retrograde access to the contralateral main
body leg, depending on the particular patient’s anatomy.
Sizing considerations are different for balloon-expand-
able stent grafts compared with self-expanding stent-grafts.
Significant oversizing has been advocated for self-expand-
ing stent grafts, as a hedge against late endoleak, chiefly on
the basis of data from the EuroSTAR registry.7 However,
oversizing may be associated with a higher incidence of late
neck dilatation and subsequent graft migration.8 With a
balloon- expandable stent graft, however, sizing is tailored
to the internal diameter of the target vessel, with minimal
oversizing. In this trial, the amount of oversizing was
determined with preoperative CTA-based measurements.
We have observed no instances of late-attachment endoleak
with this strategy. Oversizing of a balloon-expandable de-
vice can result in aortic perforation, as occurred in two of
our patients.
Endoleaks were noted in only 5.9% of patients at 6
months. It has recently been noted that endoleak rates are
device- dependent,9 and with the Lifepath System we re-
port one of the lowest endoleak rates described for any
device to date.5,10-14 The endoleaks that were noted to
persist at 6 months were treatable with endovascular means
in all but one case, which was treated with open conversion.
It is important that there was no occurrence of type III or
type IV endoleaks. The graft fabric consists of full-thickness
surgical-weight woven polyester, traditionally used for
open AAA repair, which has thus far not demonstrated any
defects during follow-up.
As evidence of successful aneurysm exclusion, reduc-
tion in sac diameter and volume was observed in most
patients (84% with volume reduction at 1 year). This rep-
resents the highest rate of sac size regression reported for
any device to date.15 These significant reductions contin-
ued to accrue through every follow-up interval. Only a few
patients had observed increases in diameter or volume, and
most of these were attributable to endoleaks noted at the
same time. It is important that there were no late ruptures
or aneurysm-related deaths over the 52-month study, at-
testing to the efficacy of aneurysm exclusion.
Wireform fracture has been a problem with the Life-
path System. Fractures have been without clinical sequelae
in most patients. However, graft migration, while uncom-
mon (2.2%), was seen only in first-generation patients with
two or more fractures of the proximal three anchoring
wireforms, and one endoleak, at the proximal attachment,
was noted in association with one such migration. In re-
sponse to this early observation the wireforms were
strengthened. While there have been no clinically signifi-
cant wireform fractures since this modification, follow-up
of the second-generation of the LifePath System is too brief
to draw firm conclusions. The incidence of observed frac-
tures in the critical first three sealing wireforms has been
significantly reduced. Clearly, careful follow-up is necessary
to ensure the long-term integrity of the device.
Limitations of the Lifepath System include the rela-
tively large size of the delivery system. The main body is
delivered through a 25F (OD) sheath, requiring a mini-
mum iliac access diameter of 8 mm on one side. The
contralateral access requirement is 19F (OD). The flexible
sheath will enable passage of the device through smaller
iliac arteries, provided the vessels are not highly calcified.
We have found anecdotally that uncalcified iliac arteries as
small as 6 mm often are able to accommodate the 25F
hydrophilic sheath with its long, tapered dilator.
The skills required for successful planning and use of
the Lifepath System transfer readily from experience gained
Table VII. Aneurysm diameter and volume change after EVAR*
Diameter change
Follow-up
6 Mo 12 Mo 24 Mo
n % n % n %
Decrease 5 mm 18 30 28 58 16 73
No change 40 66 16 33 5 23
Increase 5 mm 3 4 4 8 1 4
Volume change n % n % n %
Decrease 5% 59 62 52 84 19 86
No change 22 23 6 10 0 0
Increase 5% 14 15 4 6 3 14
*See Fig 4 for graphic representation of diameters and volumes at each interval.
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in placing balloon-expandable stents. There is a learning
curve, both for sizing of grafts and implantation of devices,
for operators whose EVAR experience has been exclusively
with self-expanding stent grafts.
CONCLUSION
The Lifepath System demonstrates a low endoleak and
secondary intervention rate and high sac regression rate
compared with other devices. The unique balloon-expand-
able design offers the advantages of precise placement and
high radial force. The device appears to be highly resistant
to limb thrombosis and modular component separation.
Patients were protected from AAA rupture after successful
implantation of the device, and demonstrated significant
reduction in AAA diameter and volume. Fractures of the
wireforms of the main body of the device have been ob-
served. Careful follow-up of patients after EVAR is neces-
sary.
APPENDIX
The Lifepath AAA Graft System Investigators. Jens
Allenberg, MD, University of Heidelberg, Heidelberg,
Germany; Alain Branchereau, MD, Hospital de la Timone,
Marseille, France; Hugh G. Beebe, MD, Jobst Vascular
Center, Toledo, Ohio; David C. Brewster, MD, Massachu-
setts General Hospital, Boston, Mass; Jeffrey P. Carpenter,
MD, University of Pennsylvania, Philadelphia, Pa; John
Crouch, MD, St. Luke’s Medical Center, Milwaukee, Wis;
R. Clement Darling, MD, Albany Medical Center, Albany,
NY; Mark Fillinger, MD, Dartmouth Hitchcock Medical
Center, Lebanon, NH; Roy Fujitani, MD, University of
California, Irvine, Calif; Berndt Glucklich, MD, Kreiskran-
kenhaus Rendsburg, Rendsburg, Germany; Roy Green-
berg, MD, Cleveland Clinic Foundation, Cleveland, Ohio;
Svante Horsch, MD, Krankenhaus Porz am Rhein, Koln,
Germany; K. Craig Kent, MD, New York Hospital, New
York, NY; Chris Kwolek, MD, University of Kentucky,
Lexington, Ky; Werner Lang, MD, Klinikum der Friedrich-
Alexander-Universitat, Erlangen, Germany; Graham Long,
MD, William Beaumont Hospital, Detroit, Mich; Michel
Makaroun, MD, University of Pittsburgh, Pittsburgh, Pa;
John Martin, MD, Anne Arundel Vascular Institute, Prince
Frederick, Md; Richard McCann, MD, Duke University,
Durham, NC; William McKinsey, MD, University of Chi-
cago, Chicago, Ill; Andre Nevelsteen, MD, Dienst
Vaatheelkunde, Leuven, Belgium; Geoffrey White, MD,
Royal Prince Alfred Hospital, Camperdown, NSW, Austra-
lia; Rodney White, MD, Harbor UCLA Medical Center,
Torrance, Calif.
REFERENCES
1. White G, Yu W, May J, Stephen M, Waugh R. A new nonstented
baloon-expandable graft for straight or bifurcated endoluminal bypass.
J Endovasc Surg 1994;1:16-24.
2. White GH, Yu W, May J, Waugh R, Stephen M, Harris J. Three year
experience with the White-Yu GAD graft for transluminal repair of
aortic and iliac aneurysms. J Endovasc Surg 1997;4:124-36.
3. Chaikof E, Blankensteijn JD, Harris P, White GH, Zarins CK, Bernhard
VM, et al. Reporting standards for endovascular abdominal aortic
aneurysm repair. J Vasc Surg 2002;35:1048-60.
4. Carpenter JP, Neschis DG, Fairman RM, Barker CF, Golden MA,
Velazquez OC, et al. Failure of endovascular abdominal aortic aneurysm
graft limbs. J Vasc Surg 2001;33:296-302; discussion 302-3.
5. Zarins CK, White RA, Moll FL, Crabtree T, Bloch DA, Hodgson KJ, et
al. The AneuRx stent graft: four-year results and worldwide experience
2000. J Vasc Surg 2001;33(suppl 2):S135-45.
6. Dias N, Resch T, Malina M, Lindblad B, Ivancev K. Intraoperative
proximal endoleaks during AAA stent-graft repair: evaluation of risk
factors and treatment with Palmaz stents. J Endovasc Ther 2001;8:268-
73.
7. Mohan IV, Laheij RJ, Harris PL. Risk factors for endoleak and the
evidence for stent-graft oversizing in patients undergoing endovascular
aneurysm repair. Eur J Vasc Endovasc Surg 2001;21:344-9.
8. Conners M, Sternbergh W, Carter G, Tonnessen B, Yoselevitz M,
Money S. Endograft migration one to four years after endovascular
aortic aneurysm repair with the AneuRx device: a cautionary note. J Vasc
Surg 2002;36:476-84.
9. Ouriel K, Clair D, Greenberg R, Lyden SP, O’Hara PJ, Sarac TP, et al.
Endovascular repair of abdominal aortic aneurysms: device-specific out-
come. J Vasc Surg 2003;37:991-8.
10. Chuter TA, Faruqi RM, Sawhney R, et al. Endoleak after endovascular
repair of abdominal aortic aneurysm. J Vasc Surg 2001;34:98-105.
11. Criado FJ, Wilson EP, Fairman RM, Abul-Khoudoud O, Wellons E.
Update on the Talent aortic stent-graft: a preliminary report from
United States phase I and II trials. J Vasc Surg 2001;33(suppl 2):
S146-9.
12. Makaroun MS, Chaikof E, Naslund T, Matsumura JS. Efficacy of a
bifurcated endograft versus open repair of abdominal aortic aneurysms:
a reappraisal. J Vasc Surg 2002;35:203-10.
13. Carpenter JP. Multicenter trial of the PowerLink bifurcated system for
endovascular aortic aneurysm repair. J Vasc Surg 2002;36:1129-37.
14. Parent F, Meier G, Godziachvili V, LeSar CJ, Parker FM, Carter KA, et
al. The incidence and natural history of type I and II endoleak: a 5-year
follow-up assessment by color duplex ultrasound. J Vasc Surg 2002;35:
474-81.
15. Bertges D, Chow K, Wyers M, Landsittel D, Frydrych AV, Stavropoulos
W, et al. Abdominal aortic aneurysm size regression after endovascular
repair is endograft dependent. J Vasc Surg 2003;37:716-23.
Submitted Jun 11, 2003; accepted Oct 14, 2003.
DISCUSSION
Dr Richard M. Green (Rochester, NY). Dr. Carpenter, that
was nicely presented. Can you give us a sense—you’ve used a lot of
different devices—as to what the specific role of this graft will be,
what the advantages are, disadvantages are, relative to some of the
others. There are a lot of the same anatomic indications for the
currently approved devices.
Dr Jeffrey P. Carpenter. That’s an excellent question: Where
does this device fit in?
I think what distinguishes it from the other devices, of course,
is the fact that it’s a balloon-expandable device. It offers the ability
to make very fine adjustments during deployment. It deploys quite
accurately.
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